A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,305,371 shares of MREO stock, worth $4.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,305,371
Previous 1,762,003 25.92%
Holding current value
$4.37 Million
Previous $6.34 Million 15.42%
% of portfolio
0.01%
Previous 0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.45 - $4.87 $1.58 Million - $2.22 Million
-456,632 Reduced 25.92%
1,305,371 $5.37 Million
Q2 2024

Aug 09, 2024

BUY
$2.58 - $4.25 $231,410 - $381,199
89,694 Added 5.36%
1,762,003 $6.34 Million
Q1 2024

May 13, 2024

SELL
$2.3 - $4.05 $289,110 - $509,085
-125,700 Reduced 6.99%
1,672,309 $5.52 Million
Q4 2023

Feb 13, 2024

BUY
$1.19 - $2.42 $83,822 - $170,462
70,439 Added 4.08%
1,798,009 $4.15 Million
Q3 2023

Nov 14, 2023

SELL
$1.15 - $1.67 $58,882 - $85,507
-51,202 Reduced 2.88%
1,727,570 $2.23 Million
Q2 2023

Aug 11, 2023

BUY
$0.79 - $1.43 $681,661 - $1.23 Million
862,863 Added 94.21%
1,778,772 $2.35 Million
Q1 2023

May 12, 2023

SELL
$0.71 - $1.22 $242,436 - $416,581
-341,460 Reduced 27.16%
915,909 $647,000
Q4 2022

Feb 13, 2023

BUY
$0.5 - $1.01 $11,877 - $23,992
23,755 Added 1.93%
1,257,369 $943,000
Q3 2022

Nov 14, 2022

BUY
$0.82 - $1.73 $512,258 - $1.08 Million
624,705 Added 102.59%
1,233,614 $1.06 Million
Q2 2022

Aug 12, 2022

BUY
$0.33 - $1.69 $107,285 - $549,434
325,109 Added 114.56%
608,909 $682,000
Q1 2022

May 13, 2022

BUY
$1.04 - $1.7 $65,728 - $107,440
63,200 Added 28.65%
283,800 $318,000
Q4 2021

Feb 11, 2022

SELL
$1.51 - $2.59 $269,233 - $461,797
-178,300 Reduced 44.7%
220,600 $353,000
Q3 2021

Nov 12, 2021

BUY
$2.2 - $3.17 $250,360 - $360,746
113,800 Added 39.92%
398,900 $965,000
Q2 2021

Aug 13, 2021

BUY
$2.94 - $4.08 $52,626 - $73,032
17,900 Added 6.7%
285,100 $904,000
Q1 2021

May 13, 2021

SELL
$2.6 - $4.43 $239,200 - $407,560
-92,000 Reduced 25.61%
267,200 $900,000
Q4 2020

Feb 10, 2021

BUY
$1.95 - $3.6 $659,100 - $1.22 Million
338,000 Added 1594.34%
359,200 $1.29 Million
Q3 2020

Nov 13, 2020

SELL
$2.55 - $3.29 $74,460 - $96,068
-29,200 Reduced 57.94%
21,200 $56,000
Q2 2020

Aug 13, 2020

BUY
$1.0 - $3.4 $50,400 - $171,360
50,400 New
50,400 $154,000
Q1 2020

May 14, 2020

SELL
$0.8 - $3.21 $101,058 - $405,496
-126,323 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$1.1 - $3.7 $43,780 - $147,260
-39,800 Reduced 23.96%
126,323 $414,000
Q3 2019

Nov 13, 2019

SELL
$2.22 - $4.14 $66,156 - $123,371
-29,800 Reduced 15.21%
166,123 $495,000
Q2 2019

Aug 12, 2019

BUY
$2.52 - $6.5 $493,725 - $1.27 Million
195,923 New
195,923 $494,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $419M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.